RENVA covers women's health / hrt telehealth providers with independent pricing research and comparison guides. All affiliate relationships are disclosed. No medical advice.
What 'bioidentical' actually means, what the evidence says about who benefits most, and how HRT guidance has changed since the original WHI trial.
What actually distinguishes perimenopause from menopause, the real symptom range, and why guidelines recommend against routine hormone testing for most women.
Oral, transdermal, and vaginal estrogen aren't interchangeable — how they differ in risk, mechanism, and what each is meant to treat.
What's actually FDA-approved, what compounding covers, and what NASEM's 2020 review found.
What guidelines actually recommend for baseline assessment, when hormone testing genuinely helps, and what ongoing monitoring looks like.
Hormones aren't controlled substances, so HRT telehealth runs on a different regulatory track than TRT — what a legitimate evaluation looks like.
A practical walkthrough of intake, evaluation, prescribing, and follow-up — and where compounded and FDA-approved sourcing differ.
Menopause symptoms are common and treatable — here's the realistic symptom pattern worth discussing with a clinician, what else can mimic it, and when to actually book that visit.
Progesterone's main job in HRT is protecting the uterine lining — here's how that works, why FDA-approved micronized progesterone stands out, and what the real breast-cancer evidence actually shows.
Why HRT pricing varies so much between providers — membership structure, delivery method, compounded vs. FDA-approved sourcing, and insurance all shift the real cost.
PT-141 isn't 'female Viagra' — it's a centrally acting medication FDA-approved for a specific, narrow diagnosis. Here's the real mechanism, evidence, and regulatory scope.
Bremelanotide is FDA-approved — but only as one specific product, for one specific diagnosis. Here's exactly what that means, and why 'compounded PT-141' is a genuinely different thing.
Oxytocin's nickname as the 'bonding hormone' has outpaced the actual trial evidence for treating low libido. Here's an honest look at what the research really found.
One has FDA approval and phase 3 trial evidence behind it for a specific diagnosis. The other has a plausible mechanism and consistently underwhelming trial results.
HSDD is a real, distressing condition with a specific clinical definition — but low desire alone isn't automatically a diagnosis. Here's how it's actually assessed.
Vyleesi, a hypothetical generic, and compounded "PT-141" would all go through completely different FDA pathways.
Why sexual wellness pricing varies — treatment type, delivery route, and FDA-approved vs. compounded sourcing all shift the real cost.
Menopause hormone therapy and sexual wellness care answer different clinical questions — here's how they overlap, where they diverge, and why the right starting point is your actual symptom pattern.
The licensure rules, evaluation standards, and transparency signals that separate a legitimate HRT or sexual wellness provider from a red flag.
A practical checklist of questions to get clear answers to before payment — clinical purpose, clinician authorization, medication sourcing, and exit terms.
Affiliate disclosure: RENVA may earn affiliate commissions from some provider links. Affiliate relationships do not influence provider scoring or editorial conclusions. Full disclosure →
Medical disclaimer: RENVA is not a healthcare provider. Content is informational and educational only. Always consult a licensed healthcare professional before making health decisions. Full disclaimer →